Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Rinvoq
Synonyms :
upadacitinib
Class :
Antirheumatics, JAK Inhibitors
Brand Name :
Rinvoq
Synonyms :
upadacitinib
Class :
Antirheumatics, JAK Inhibitors
Dosage Forms & StrengthsÂ
Tablet, extended releaseÂ
15mgÂ
Dosage Forms & StrengthsÂ
Tablet, extended releaseÂ
15mgÂ
may have an increased immunosuppressive effect when combined with upadacitinib
may have an increased immunosuppressive effect when combined with upadacitinib
may have an increased immunosuppressive effect when combined with upadacitinib
may have an increased immunosuppressive effect when combined with upadacitinib
may have an increased immunosuppressive effect when combined with upadacitinib
may decrease the therapeutic effect when combined with COVID-19 vaccines
may enhance the serum concentration when combined with upadacitinib
may enhance the serum concentration when combined with upadacitinib
may enhance the serum concentration when combined with upadacitinib
may enhance the serum concentration when combined with upadacitinib
may enhance the serum concentration when combined with upadacitinib
may enhance the serum concentration of CYP3A4 inhibitors
may have an increased immunosuppressive effect when combined with upadacitinib
the immunosuppressive effect of either of the drugs is raised, leading to increased chances of infection
immunosuppressants increase the effect of immunosuppression of upadacitinib
immunosuppressants increase the effect of immunosuppression of upadacitinib
immunosuppressants increase the effect of immunosuppression of upadacitinib
immunosuppressants increase the effect of immunosuppression of upadacitinib
immunosuppressants increase the effect of immunosuppression of upadacitinib
may have an increased immunosuppressive effect when combined with upadacitinib
may have an increased immunosuppressive effect when combined with upadacitinib
may have an increased immunosuppressive effect when combined with upadacitinib
It may enhance the immunosuppressive effects when combined with risankizumab
upadacitinib: they may increase the immunosuppressive effect of immunostimulants
upadacitinib: they may increase the immunosuppressive effect of immunostimulants
upadacitinib: they may increase the immunosuppressive effect of immunostimulants
upadacitinib: they may increase the immunosuppressive effect of immunostimulants
upadacitinib: they may increase the immunosuppressive effect of immunostimulants
upadacitinib: they may increase the immunosuppressive effect of selective immunosuppressants
upadacitinib: they may increase the immunosuppressive effect of selective immunosuppressants
upadacitinib: they may increase the immunosuppressive effect of selective immunosuppressants
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both the drugs are combined, the risk or severity of adverse effects increases    
risk of severe infection due to immunosuppressive effects, avoid combination
when both drugs are combined, the risk or severity of adverse effects increases  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
the effect of upadacitinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of upadacitinib 
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
immunosuppressants increase the immunosuppressive activity of upadacitinib
may increase the immunosuppressive effects
may increase the immunosuppressive effect of immunosuppressive agents
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
antithymocyte globulin equineÂ
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may diminish the serum concentration when combined with upadacitinib
may diminish the serum concentration when combined with upadacitinib
may diminish the serum concentration when combined with upadacitinib
may diminish the serum concentration when combined with upadacitinib
may diminish the serum concentration when combined with upadacitinib
It may enhance the effects when combined with rozanolixizumab by immunosuppressive effects
when both drugs are combined, there may be an increase in adverse/toxic effects of immunosuppression and the risk of severe infection
may diminish the serum concentration of CYP3A4 Inducers
Actions and spectrum:Â
upadacitinib is a Janus kinase (JAK) inhibitor, specifically targeting JAK1. JAKs are intracellular enzymes involved in the JAK-STAT signaling pathway, which is important in immune cell signaling and activation.
By inhibiting JAK1, upadacitinib interferes with the activity of multiple cytokines, including interleukin (IL)-2, IL-4, IL-6, IL-7, IL-9, IL-15, and IL-21, which are involved in immune and inflammatory responses.
upadacitinib is used for the treatment of several autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.Â
Frequency definedÂ
>10%Â
RAÂ
ADÂ
1-10%Â
RAÂ
PsAÂ
ADÂ
<1%Â
RAÂ
Frequency not definedÂ
RAÂ
Black Box Warning Â
upadacitinib may increase the risk of infections that lead to hospitalization or death. Patients should be closely monitored for signs of infection and treated promptly.Â
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Comorbidities:Â
Pregnancy consideration: pregnancy category DÂ
Lactation: safety and efficacy not established Â
Pregnancy category:Â
Â
Pharmacology:Â
upadacitinib is a Janus kinase (JAK) inhibitor that exerts its pharmacological effects by selectively inhibiting the activity of JAK1, a type of intracellular enzyme involved in the signaling pathways of various cytokines involved in the immune response.
By inhibiting JAK1, upadacitinib prevents the phosphorylation of STAT proteins, which leads to the modulation of gene expression and subsequent immunological and inflammatory responses.Â
upadacitinib has been shown to reduce the production of pro-inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-12 (IL-12), and interferon-gamma (IFN-Îł), which are involved in the pathogenesis of autoimmune and the inflammatory diseases. It also modulates the differentiation and function of immune cells, T cells, B cells, and NK cells, which play a important role in the regulation of immune responses. Â
Pharmacodynamics:Â
upadacitinib is a selective and reversible JAK1 inhibitor that exerts its pharmacological effects by inhibiting JAK-mediated signaling of a range of cytokines including interleukin (IL)-2, IL-4, IL-6, IL-7, IL-9, IL-15, and IL-21, which are involved in the pathogenesis of several autoimmune and inflammatory diseases.
By blocking JAK1, upadacitinib prevents the phosphorylation of STATs (signal transducer and activator of transcription), thereby inhibiting downstream inflammatory signaling pathways. This leads to a reduction in the production of pro-inflammatory cytokines and chemokines, and a subsequent decrease in inflammation and symptoms of autoimmune and inflammatory diseases. Â
Pharmacokinetics:Â
AbsorptionÂ
upadacitinib is rapidly absorbed after oral administration, with a median time to maximum concentration (Tmax) of 1 to 2 hours. Its absolute bioavailability is approximately 74%. Â
DistributionÂ
The volume of distribution of upadacitinib is moderate, estimated to be approximately 1072 L. It is highly protein-bound (>99%), primarily to albumin. Â
MetabolismÂ
upadacitinib undergoes hepatic metabolism mainly via cytochrome P450 (CYP) 3A4. The major metabolite is formed via oxidation and is pharmacologically inactive. Â
Elimination and excretionÂ
The elimination half-life of upadacitinib is approximately 6 to 14 hours. Approximately 71% of the drug is eliminated in the feces, while 14% is eliminated in the urine, mainly as metabolites.Â
Administration:Â
upadacitinib is an oral medication that comes in the form of tablets. It should be taken once daily with or without food. The recommended dose of upadacitinib may vary depending on the condition being treated and other factors such as age, weight, and other medications being taken. It is important to follow the prescribing healthcare provider’s instructions on dosing and administration.Â
Patient information leafletÂ
Generic Name: upadacitinibÂ
Pronounced: (ew-PAD-É™-SY-ti-nib)Â Â
Why do we use upadacitinib?Â
upadacitinib is a medication used in the treatment of rheumatoid arthritis in patients who have not responded well to other treatments or have intolerable side effects.
It is used for the treatment of active psoriatic arthritis in adults, and active ankylosing spondylitis in patients who have not responded well to other treatments or have intolerable side effects.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
